| Year |
Citation |
Score |
| 2024 |
Yang Z, Mogre S, He R, Berdan EL, Ho Sui SJ, Hill SJ. The ORFIUS complex regulates ORC2 localization at replication origins. Nar Cancer. 6: zcae003. PMID 38288445 DOI: 10.1093/narcan/zcae003 |
0.326 |
|
| 2020 |
Wan C, Keany MP, Dong H, Al-Alem LF, Pandya UM, Lazo S, Boehnke K, Lynch KN, Xu R, Zarrella DT, Gu S, Cejas P, Lim K, Long HW, Elias KM, ... ... Hill SJ, et al. Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high grade serous ovarian cancer. Cancer Research. PMID 33158814 DOI: 10.1158/0008-5472.CAN-20-1674 |
0.417 |
|
| 2020 |
Bouberhan S, Philp L, Hill S, Al-Alem LF, Rueda B. Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer. Cancers. 12. PMID 32403357 DOI: 10.3390/cancers12051206 |
0.3 |
|
| 2020 |
Hill SJ, Lizotte P, Kesten N, Horowitz NS, Muto MG, Worley MJ, Feltmate CM, Berkowitz RS, Long H, Matulonis UA, Crum CP, Brown M, D'Andrea AD. Abstract PR06: Dissecting mechanisms of replication fork stabilization in patient-derived high-grade serous organoid cultures and their impact on therapeutic sensitivity and the immune-tumor interaction Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Ovca19-Pr06 |
0.574 |
|
| 2019 |
Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, Campos S, Lindeman NI, Hill S, Stover E, Schumer S, et al. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901021. PMID 31461377 DOI: 10.1200/Jco.19.01021 |
0.45 |
|
| 2019 |
Hill SJ, Decker B, Roberts EA, Yang C, Horowitz NS, Muto MG, Worley MJ, Feltmate CM, Nucci MR, Swisher EM, Morizane R, Kochupurakkal B, Do KT, Konstantinopoulos P, Liu JF, et al. Abstract AP10: REAL-TIME ASSESSMENT OF HGSC DNA DAMAGE REPAIR DEFECTS AND DEFECT-INDUCED RESPONSE TO THERAPY IN OVARIAN CANCER ORGANOIDS Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Ap10 |
0.527 |
|
| 2019 |
Hill SJ, Lizotte P, Horowitz NS, Muto MG, Worley MJ, Feltmate CM, Kochupurakkal B, Do KT, Konstantinopoulos P, Nucci MR, Liu JF, Matulonis UA, Shapiro GI, Berkowitz RS, Crum CP, et al. Abstract 368A: Functional assessment of DNA damage repair defects and the anti-tumor immune response in high grade serous ovarian cancers using patient-derived organoids Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-368A |
0.527 |
|
| 2019 |
Do KT, Hill SJ, Kochupurakkal B, Supko JG, Gannon C, Anderson A, Muzikansky A, Wolanski A, Hedglin J, Parmar K, Lazaro J, Liu J, Campos S, Matulonis UA, D'Andrea AD, et al. Abstract CT232: Phase I combination study of the CHK1 inhibitor prexasertib (LY2606368) and olaparib in patients with high-grade serous ovarian cancer and other advanced solid tumors Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct232 |
0.384 |
|
| 2018 |
Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ, Feltmate CM, Nucci MR, Swisher EM, Nguyen H, Yang C, Morizane R, Kochupurakkal BS, Do KT, Konstantinopoulos PA, et al. Prediction of DNA Repair Inhibitor Response in Short Term Patient-Derived Ovarian Cancer Organoids. Cancer Discovery. PMID 30213835 DOI: 10.1158/2159-8290.Cd-18-0474 |
0.507 |
|
| 2018 |
Aref AR, Campisi M, Ivanova E, Portell A, Larios D, Piel BP, Mathur N, Zhou C, Coakley RV, Bartels A, Bowden M, Herbert Z, Hill S, Gilhooley S, Carter J, et al. 3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade. Lab On a Chip. PMID 30183789 DOI: 10.1039/C8Lc00322J |
0.35 |
|
| 2016 |
Hill SJ, Mordes DA, Cameron LA, Neuberg DS, Landini S, Eggan K, Livingston DM. Two familial ALS proteins function in prevention/repair of transcription-associated DNA damage. Proceedings of the National Academy of Sciences of the United States of America. PMID 27849576 DOI: 10.1073/Pnas.1611673113 |
0.588 |
|
| 2015 |
Hatchi E, Skourti-Stathaki K, Ventz S, Pinello L, Yen A, Kamieniarz-Gdula K, Dimitrov S, Pathania S, McKinney KM, Eaton ML, Kellis M, Hill SJ, Parmigiani G, Proudfoot NJ, Livingston DM. BRCA1 recruitment to transcriptional pause sites is required for R-loop-driven DNA damage repair. Molecular Cell. 57: 636-47. PMID 25699710 DOI: 10.1016/J.Molcel.2015.01.011 |
0.552 |
|
| 2014 |
Hill SJ, Rolland T, Adelmant G, Xia X, Owen MS, Dricot A, Zack TI, Sahni N, Jacob Y, Hao T, McKinney KM, Clark AP, Reyon D, Tsai SQ, Joung JK, et al. Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage. Genes & Development. 28: 1957-75. PMID 25184681 DOI: 10.1101/Gad.241620.114 |
0.597 |
|
| 2014 |
Hill SJ, Clark AP, Silver DP, Livingston DM. BRCA1 pathway function in basal-like breast cancer cells. Molecular and Cellular Biology. 34: 3828-42. PMID 25092866 DOI: 10.1128/Mcb.01646-13 |
0.638 |
|
| 2011 |
Pathania S, Nguyen J, Hill SJ, Scully R, Adelmant GO, Marto JA, Feunteun J, Livingston DM. BRCA1 is required for postreplication repair after UV-induced DNA damage. Molecular Cell. 44: 235-51. PMID 21963239 DOI: 10.1016/J.Molcel.2011.09.002 |
0.639 |
|
| 2011 |
Ginjala V, Nacerddine K, Kulkarni A, Oza J, Hill SJ, Yao M, Citterio E, van Lohuizen M, Ganesan S. BMI1 is recruited to DNA breaks and contributes to DNA damage-induced H2A ubiquitination and repair. Molecular and Cellular Biology. 31: 1972-82. PMID 21383063 DOI: 10.1128/Mcb.00981-10 |
0.487 |
|
| Show low-probability matches. |
